Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL290 Target Snapshot

cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B · SINGLE PROTEIN · Homo sapiens

608Compounds
85Assays
3Approved Drugs
620.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q13370. Use UniProt Q13370 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q13370 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B as ChEMBL target CHEMBL290, mapped to UniProt Q13370. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL290
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q13370
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B is the right protein anchor across sources, using UniProt Q13370 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelcGMP-inhibited 3',5'-cyclic phosphodiesterase 3B
UniProt AccessionQ13370
Component TypeProtein
Sequence Length1112 aa

cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B, mapped to UniProt Q13370. Sequence length is 1112 aa.

Mapped IDQ13370
Review namecGMP-inhibited 3',5'-cyclic phosphodiesterase 3B
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

3
Approved
2
Phase III
2
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC50555.0
KI63.0
EC501.0
KD1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL338860 10.31 IC50 0.049 Preclinical
CHEMBL339210 10.17 IC50 0.068 Preclinical
CHEMBL131355 9.96 IC50 0.11 Preclinical
CHEMBL129668 9.89 IC50 0.13 Preclinical
CHEMBL131111 9.89 IC50 0.13 Preclinical
CHEMBL128456 9.72 IC50 0.19 Preclinical
CHEMBL338179 9.62 IC50 0.24 Preclinical
CHEMBL128391 9.59 IC50 0.26 Preclinical
CHEMBL128621 9.52 IC50 0.3 Preclinical
CHEMBL129283 9.48 IC50 0.33 Preclinical
Distribution

pChEMBL Value Distribution

30
5.0
38
5.5
65
6.0
165
6.5
111
7.0
33
7.5
25
8.0
4
8.5
9
9.0
8
9.5
pChEMBL
Approved Drugs

Approved Drugs

CILOSTAZOL
CHEMBL799
Approved 1999
MILRINONE
CHEMBL189
Approved 1987
Assay Landscape

Assay Landscape

85
Total Assays
523
Tested Compounds
3
Assay Types
Binding — 82 assays, 523 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 56 162 5.8
cell-based format 24 42 6.6
assay format 2 319 7.2
ADME — 2 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 0
single protein format 1 0
Functional — 1 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 1 7.3

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine